FLNA — Filana Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Cassava Sciences Q3 Basic EPS USD -0.61
Brief: Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
Cassava Sciences Inc expected to post a loss of 77 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Silver miners, Instacart, Incyte
U.S. STOCKS ON THE MOVE-Energy sector, Sigma Additive Solutions, Newmont Corp
U.S. STOCKS ON THE MOVE-T2 Biosystems, Dollar General, Wells Fargo
developer
developer of Cassava's potential Alzheimer's drug cited for 'egregious misconduct'- Science
Brief: Cassava Sciences Completes Patient Enrollment For Pivotal Phase 3 Trial Of Oral Simufilam In Alzheimer's Disease
Incyte slides as GSK's bone marrow cancer therapy gets FDA nod
Cassava Sciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cassava Sciences Reports Q2 2023 Financial Results And Operating Updates
Brief: Cassava Sciences Q2 Basic EPS USD -0.63
Cassava Sciences Inc expected to post a loss of 59 cents a share - Earnings Preview
Cassava Sciences down as Alzheimer's disease drug study fails to impress
Brief: Oral Simufilam Slowed Cognitive Decline In A Randomized Withdrawal Trial Of Mild-To-Moderate Alzheimer's Disease
Live Markets: Digimarc among top 'squeeze' targets -S3 Partners
Cassava up after dosing completed in controlled Alzheimer's drug trial
Brief: Cassava Sciences Completes Patient Dosing In A Randomized Controlled Trial Of Simufilam In Alzheimer’S Disease